Introduction

Osteoarthritis (OA) is a degenerative disorder of the joints that causes significant pain and functional disability. OA involves not only the articular cartilage, but also the subchondral bone, ligaments, synovial membrane and periarticular muscle (Chen et al., 2010; Henrotin and Kurz, 2007; Krasnokutsky et al., 2008). The cause of OA is unknown, but several studies have suggested that this joint degeneration results from the combination of mechanical stress and biochemical factors, and mainly reactive oxygen species (ROS) and matrix metalloproteinases (MMPs) (Henrotin and Kurz, 2007).

ROS such as the superoxide anion (O2-), hydrogen peroxide (H2O2) and hydroxyl radicals (OH) act as a physiological defense system against microbial infection and they are involved in maintaining normal cellular functions and intracellular signal transduction (Filippin et al., 2008). However, as ROS are capable of damaging lipids, proteins, DNA and the extracellular matrix, excess ROS are removed by antioxidants (Dröge, 2002).

Ultimately, oxidative stress refers to a cellular state in which the production of ROS is elevated and/or the levels of antioxidants are reduced. There is much evidence indicating that oxidative stress is involved in the pathogenesis of OA. Increased ROS promote cartilage degradation by inhibiting cartilage matrix synthesis and inducing chondrocyte apoptosis and cartilage matrix breakdown (Henrotin et al., 2005). The serum total antioxidant capacity, the thiol level and the catalase activity of OA patients are low (Altindag et al., 2007). The cartilage from patients with OA contains less extracellular antioxidants such as superoxide dismutase than does normal cartilage (Regan et al., 2005). The levels of nitrated type II collagen peptides in the sera of patients with OA are elevated, which is indicative of the formation of peroxynitrite (ONOO-), which is a marker of oxidative stress (Deberg et al., 2005).

Intra-articular injection of monosodium iodoacetate (MIA) induces disorganization of the articular cartilage by inhibiting the activity of glyceraldehyde-3-phosphate dehydrogenase in chondrocytes, and this results in disruption of glycolysis and eventual cell death. These chondrocytes have similar histopathology to that of human OA and the MIA induced OA animal model closely mimics both the pain and structural changes associated with the disease (Janusz et al., 2001; Bove et al., 2003).

Grape seed extract contains lipids, proteins, carbohydrates and polyphenols. Proanthocyanidins are potent natural antioxidants, and they are the most abundant phenolic compounds in grape seeds and they are high molecular weight polymers comprised of dimers or trimers of (+)-catechin and (-)-epicatechin (Fine, 2000). It has been suggested that grape seed proanthocyanidin extract (GSPE) is an effective therapy for oxidation-related diseases in animal models of tumors, atherosclerosis, gastric ulcers, cataracts, diabetic retinopathy and rheumatoid arthritis (Ray et al., 2001; Sato et al., 2001; Pataki et al., 2002; Durukan et al., 2006; Cho et al., 2009; Prasain et al., 2009). However, its effects on the chronic pain and structural damage relevant to the pain in OA have not been investigated. We examined whether GSPE relieves pain and if it prevents the structural changes known to cause pain in a rat model of OA produced by MIA injection.

Results

Effects of GSPE on the pain in the MIA-induced OA model

The mechanical paw withdrawal thresholds to von Frey stimuli were measured for 4 weeks after MIA injection using a dynamic plantar esthesiometer. Four days after the injection of MIA, the paw withdrawal latency (PWL) and paw withdrawal threshold (PWT) were lower in the MIA-treated group than in the nonarthritis group, which had received a saline injection instead of MIA. However, the PWL and PWT were significantly higher in the GSPE-treated groups (100 mg/kg: data not shown, 300 mg/kg) than in the MIA-treated group (P < 0.01). Seven days after the injection of MIA, the PWL and PWT in the GSPE-treated groups had recovered to a greater extent than that in the MIA-treated group (P < 0.05) and this trend was maintained for 4 weeks (Figures 1A and 1B).

Figure 1
figure 1

Effects of GSPE on the pain in MIA-induced OA. An experimental model of OA in rats was induced by intraarticular injection of monosodium iodoacetate (MIA) into the knee joint. Oral treatment with GSPE (100 mg/kg or 300 mg/kg given three times per week) or with vehicle was initiated on MIA injection (day 0). (A) The paw withdrawal latency and (B) paw withdrawal threshold were measured by a dynamic plantar aesthesiometer and this was compared with that of the MIA-treated group. △: nonarthritis group, ▲: MIA-treated group, ◇: MIA-treated rats treated with 300 mg/kg GSPE. *P < 0.05, **P < 0.01 compared with the MIA injection group. (C) Weight bearing was measured by an incapacitance tester and this was compared with that of the MIA-treated group at 4 weeks after the injection of MIA. *P < 0.05 compared with the MIA injection group. The experiment was repeated 3 times with similar results.

Full size image

Hind limb weight bearing is a measure of pain and this was measured using an incapacitance tester. Four weeks after the MIA injection, the hind limb weight bearing of the ipsilateral limb was significantly lower in the MIA-treated group than that in the nonarthritis group. The 300 mg/kg GSPE treated group exhibited significant recovery of hind limb weight bearing (P < 0.05, Figure 1C).

OA is characterized not only by progressive cartilage destruction, but also by alterations in bone such as osteoclast recruitment to subchondral bone and osteophyte formation. Osteophytes are also called bone spurs, and they are smooth outgrowths of bone that build up on the edges of joints due to OA. Therefore, we analyzed the osteoclastic activity and osteophyte formation. At 4 weeks after MIA injection along with GSPE treatment, histological analysis revealed osteoclasts on the subchondral bone fragmented trabeculae of the MIA-treated group (arrow), but GPSE decreased osteoclast generation (Figure 2A). We used micro-CT to examine the direct effect of GSPE on the MIA-induced osteophyte formation. Osteophytes were detected in the MIA-treated group, but not in the GSPE-treated groups (Figure 2B). In our rat model of OA, the histological and micro-CT analyses showed that treatment with 300 mg/kg of GSPE suppressed osteoclasts and the osteophyte formation.

Figure 2
figure 2

Osteoclastic activity and osteophyte formation for 4 weeks after MIA injection. Bone and osteophyte formation was evaluated in the hematoxylin and eosin-stained, paraffin-embedded knee joint sections and micro-CT analysis of the MIA injected rats treated with GSPE or vehicle, respectively. (A) Osteoclast generation was assessed using hematoxylin and eosin. The bar graphs represent the mean values ± SD of the cells that stained positive (original magnification × 200). **P < 0.01 compared with the MIA injection group. (B) Osteophyte analysis using Micro-CT.

Full size image

Effects of GSPE on the articular cartilage damage and the catabolic activity of chondrocytes

We assessed damage to the articular cartilage surface by using India ink at 4 weeks after the MIA injection. Grossly, the normal joints revealed smooth and shiny articular surfaces. The knees of the MIA-treated group showed irregular abrasions at the articular cartilage surfaces of the femoral condyle and the tibial plateau, but the 300 mg/kg GSPE-treated group had smoother articular surfaces than the MIA-treated group (Figure 3). We used hematoxylin and eosin, Safranin O fast green and toluidine blue staining to examine the structural changes in the joints. The joint from non-induced rat showed smooth articular cartilage surfaces with the underneath layer of flattened chondrocytes in the tangential zone. The chondrocytes were normally distributed in parallel rows in the transitional and radial zones of the articular cartilage. The MIA-treated group showed degeneration of the articular cartilage and disappearance of chondrocytes and proteoglycan in the tangential, transitional and radial zones of the cartilage after 2 weeks, and more severe structural changes after 4 weeks (Figures 4A and 4B). Treatment with 100 mg/kg of GSPE had little effect on the structural changes in the joints, but treatment with 300 mg/kg of GSPE resulted in less severe damage to the articular cartilage compared with that of the MIA-treated group, and chondrocytes and proteoglycan were present in the articular cartilage. The severity of OA lesion was graded using the modified Mankin scoring system. The modified Mankin scores were significantly lower in the GSPE treated group than in the MIA-treated group (Figure 4C). We observed extensive areas of loosely arranged spindle cells contained within a fine stroma instead of subchondral bone marrow in the MIA-treated group. There was a reduction in trabecular connectivity in the MIA-treated group (Figure 4D, arrow). The cartilage of the 300 mg/kg GSPE group was similar to that of the nonarthritis group.

Figure 3
figure 3

Microscopic analysis of the damaged cartilage in the femoral and tibial articular cartilage of an OA rat model using India ink staining at 4 weeks after MIA injection. The gross morphological changes of the femoral condyles and tibial plateau were photographed using a digital camera with application of India ink to contrast the cartilage lesions.

Full size image
Figure 4
figure 4

Histologic analysis of the OA joints after treatment with GSPE in MIA-induced arthritis. The knee joints from the OA rats treated with GSPE or vehicle were stained with hematoxylin and eosin , Safranin O fast green, and toluidine blue (original magnification ×100 for hematoxylin and eosin and ×200 for Safranin O fast green and toluidine blue). (A) Two weeks after the injection of MIA and (B) 4 weeks after the injection of MIA. (C) The OA lesion was graded on a scale of 0-13 using the modified Mankin scoring system with a combined score of structure, cellular abnormalities and matrix staining. *P < 0.05, **P < 0.01, ***P < 0.001 compared with the MIA injection group. (D) Femoral condyle 14 days after the MIA injection (original magnification ×100).

Full size image

We analyzed the MMP13 expression, which is a key catabolic enzyme, to assess the effects of GSPE on the catabolic activity of chondrocytes. Positive immunohistochemical reactivity to MMP13 was visualized as brown cytoplasmic and nuclear staining. No positive staining for MMP13 was observed in the normal cartilage. The strong expression of cytoplasmic and nuclear MMP13 was observed in the MIA-treated group. The MMP13 expression in the cartilage was decreased by GSPE (Figure 5). This result suggests that GSPE can reduce the activity of the catabolic enzyme MMP13 and this enzyme has been implicated in cartilage breakdown.

Figure 5
figure 5

The MMP13 expression in synovium and cartilage in the OA model using immunohistochemistry at 4 weeks after MIA injection. Immunohistochemistry was performed on representative sections of the joints from the MIA-injected rats treated with GSPE or with vehicle. The positive cells are brown; the nuclei were counterstained with hematoxylin. The bar graphs represent the mean values ± SD of the positively stained cells (original magnification ×400). *P < 0.05, **P < 0.01 compared with the MIA injection group.

Full size image

Immunohistochemical assessment of the IL-1β and nitrotyrosine expressions after treatment with GSPE in the OA rat model

The cytokines produced by the chondrocytes, and especially IL-1β, play a significant role in the degradation of cartilage. IL-1β is the main cytokine instigator of cartilage degeneration in arthritis, and it induces MMP in chondrocytes. To confirm the cartilage protective activity of GSPE, we immunostained for the IL-1β expression in cartilage and subchondral bone. We observed an increased IL-1β expression on the cartilage of the MIA-treated group. However, IL-1β was markedly decreased in the GSPE treated group. We performed immunohistochemical staining for nitrotyrosine, which is a marker for oxidant stress, to determine whether antioxidant activity is responsible for the antinociceptive effect of GSPE and its protective effect against structural damage to knee joints. Nitrotyrosine was not detected in the cartilage or synovium of the nonarthritis group, but it was detected in the cartilage and chondrocytes of the MIA-treated group (Figure 6). The nitrotyrosine staining of cartilage and synovium was reduced in the high-dose GSPE group.

Figure 6
figure 6

Immunohistochemical analysis of the IL-1β and nitrotyrosine expressions after treatment with GSPE in the MIA-induced arthritis models at 4 weeks after MIA injection. The positive cells are brown; the nuclei were counterstained with hematoxylin. The slides of the representative sections showed the expression of IL-1β or nitrotyrosine (original magnification × 400).

Full size image

Discussion

Oxidative stress is associated with the development of OA and the beneficial therapeutic effects of antioxidants such as vitamin E and vitamin C have been demonstrated in clinical trials and in animal studies of OA (Canter et al., 2007). However, the effects of antioxidants on the symptoms and structural changes of OA are controversial (Henrotin and Kurz, 2007). Henrotin and Kurz suggested that drugs with high antioxidant activity could be used as therapeutic modalities for OA (Henrotin and Kurz, 2007). GSPE has higher antioxidant activity than other well-known antioxidants such as vitamin C, vitamin E and gallic acid (Ariga, 2004). Further, the polyphenols in GSPE have already shown beneficial antioxidant effects on other oxidative stress-associated diseases (Cho et al., 2009). Thus, our present data show that GSPE treatment led to a significant reduction of the pain and structural changes in MIA induced OA rats. To the best of our knowledge, this is the first report to demonstrate the effects of GSPE on MIA-induced OA of the knee joint in rats.

We showed that GSPE treatment resulted in a significant decrease in chondrocyte damage and proteoglycan loss in MIA-induced OA. These results are similar to those of a recent study by Miller et al. in which they demonstrated that a proanthocyanidin-rich Amazonian genonutrient has chondroprotective effects in human chondrocytes (Miller et al., 2007). As mentioned earlier, the degradation of cartilage results from the imbalance between the mechanical stresses and catabolic activity, and the latter is mainly controlled by ROS and MMPs. Thus, our results can be explained that the antioxidant defense of GSPE decreased the chondrocyte damage by scavenging ROS and MMPs, by preventing their formation or by repairing the damage.

We utilized nitrotyrosine to investigate the role of GSPE and especially to probe the relationship between the antioxidant activity and antinociceptive effect of GSPE. Nitrotyrosine is an accepted marker of (NOS)-mediated oxidative damage. Nemirovskiy et al. demonstrated a modest increase in the levels of the plasma total and free 3-nitrotyrosine, which has been used as a measure of oxidative stress in an MIA rat model of OA (Nemirovskiy et al., 2009). Our present data indicates that treatment with high dose GSPE decreased nitrotyrosine production in the cartilage and synovium, and this suggests that the antioxidant activity of GSPE may contribute to reducing pain in the MIA rat model of OA.

We then analyzed the MMP13 expression to assess the effects of GSPE on the catabolic activity of chondrocytes. MMP13 is one of the most important metalloproteases involved in the osteoarthritic pathological process (Reboul et al., 1996). The MMP13 expression was significantly upregulated in the cartilage of MIA-treated rats (Barve et al., 2007). Del Carlo et al. demonstrated that pretreatment of articular chondrocytes with N-acetyl-L-cysteine, which is an antioxidant, prevented fibronectin fragment- stimulated MMP13 production (Del Carlo et al., 2007). Baragi et al. noted that MMP13 inhibitors exerted chondroprotective effects and they could potentially reduce joint pain in MIA-treated rats (Microcomputerized tomography (Micro-CT)

Micro-CT was used to develop three-dimensional images of bone. A SkyScan Desktop Micro CT 1172 (Aartselaar, Belgium) with a source voltage of 60 kV and a current of 167 µA was used to acquire the X-ray radiographs. The specimens were attached to a stage that rotated 180° and the images were acquired every 0.4°. After scanning, the cross-sectional slices were reconstructed and three-dimensional analyses were performed using CTAn SkyScan software. Each scan result was reconstructed using the same threshold values to distinguish bone and air. The bone mass and microarchitecture parameters, including the fraction of bone volume (BV), were evaluated using the built-in software of the micro-CT.